The Future 50

Rank
28
Previous: 27 Next: 29

Illumina

    The genetic-testing company hit a buzz saw when it downgraded its 2019 earnings forecast earlier this year following a slowdown in the consumer market. But the fact remains that Illumina’s platforms dominate the genomic sequencing space (its technology has helped slash the cost of whole genomic sequencing to mere thousands of dollars while considerably speeding up the process).The $44 billion company has “demonstrated an uncanny ability to out-innovate and extend its competitive lead,” according to J.P. Morgan.

    Subscribe to Fortune's Brainstorm Health Daily newsletter, where we monitor advances in healthcare and biopharma.

    Company Information

    Overall Score16
    SectorHealth Care
    IndustryLife Sciences Tools and Services
    CEOFrancis deSouza
    Websitewww.illumina.com
    HQ LocationSan Diego
    Country-
    Revenues ($M) (Past 12 Months)$3,404
    Profits ($M) (Past 12 Months)$938
    Market Value as of Oct. 9, 2019 ($M)$43,653
    Employees7,300